UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
(Address of principal executive offices and Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01. Other Events.
Recent Press Release
On December 1, 2022, the Company issued a press release announcing that it would be presenting on its cancer therapeutic research at an upcoming joint meeting of the American Society for Cell Biology (ASCB) and European Molecular Biology Organization (EMBO). The press release is filed as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. | Description | ||
99.1 | Press Release of bioAffinity Technologies, Inc., dated December 1, 2022. | ||
104 | CoverPage Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BIOAFFINITY TECHNOLOGIES, INC. | ||
By: | /s/ Maria Zannes | |
Maria Zannes | ||
President and Chief Executive Officer |
Dated: December 1, 2022
Exhibit 99.1
![]() |
News Release |
For Immediate Release
bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting
bioAffinity
reports on a potential therapeutic approach that kills cancer cells
without harm to normal cells
SAN ANTONIO, TX – Dec. 1, 2022 – bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment, today announced that David Elzi, Ph.D., bioAffinity Vice President of Research, will discuss his research into a possible mechanism by which the knock down of two genes kills cancer cells with little or no effect on normal cells at Cell Bio, a joint meeting of the American Society for Cell Biology (ASCB) and European Molecular Biology Organization (EMBO), in Washington, D.C., on Dec. 3-7, 2022. Dr. Elzi’s research supports the Company’s development of broad-spectrum cancer therapeutics.
Dr. Elzi will present a poster titled “Reassessing Cobalamin Requirements in Cell Culture” on Monday, Dec. 5, 2022, from 12:15 p.m. to 1:45 p.m. EST at the Walter E. Reed Convention Center in Washington, D.C.
“bioAffinity’s research is important in better understanding the foundation of our therapeutic platforms as it examines one potential mechanism for how silencing the genes CD320 and LRP2 together kills cancer cells but leaves normal cells unharmed,” Dr. Elzi said.
“We previously reported on the Company’s design and use of siRNAs to kill multiple cancers at the cellular level, including prostate, lung, breast, brain and skin cancers, without harm to normal cells,” said bioAffinity President and CEO Maria Zannes. “We have reported on how to deliver the potential therapy. Dr. Elzi’s recent research that will be presented next week at Cell Bio looks at why it works.”
Cell Bio 2022, the joint meeting of the ASCB and EMBO, will showcase a diverse global community of the brightest minds in cell biology in person, Dec. 3-7, 2022, in Washington, D.C. The unique meeting focuses on cell biology as the fundamental basis of biology as well as sessions on emerging interdisciplinary topics.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. The Company’s first product, CyPath® Lung, is a non-invasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. Precision Pathology Services licensed and developed CyPath® Lung as a Laboratory Developed Test (LDT) and has begun test marketing in Texas. OncoSelect® Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells. Research and optimization of the Company’s platform technologies are conducted in its laboratories at The University of Texas at San Antonio.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Company’s offering of common shares. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Contacts:
Company Contact:
Maria Zannes, President & Chief Executive Officer
mz@bioaffinitytech.com
Investor Relations Contact:
Tiberend Strategic Advisors, Inc.
Jonathan Nugent
jnugent@tiberend.com
or
David Irish
dirish@tiberend.com
>K#[,H\O-_A/TK;[OI6-9ZQHM[>21VEY9SWAY9(949ZU/,W1<
M?W
J;T M+SKL-[]=?+EJP'0R>_[P;1C&?]=?I[-:H]N_O&YZ7ZX^WCT]!;W,9%L%$X@I MP8_!5<7AS>L5(<=>S?>KWN?[WL#BG S86D2,3_?!J\UFT[.K!70'N1C* MJ)"N>V9Y2!4LE7&5'<$SKC3EP08^U$O".OC"RQ8WH&POM)%!60$-80NG(*B, MQZ8TF0)'E$UM*)*:E>EB06_U LXSNZ%;F@:JGY-0.U7M4L; MA%#++<+&ON&R9Y8-QW?]JENK%LP/W?>W2]*0"3H:,<[TJX9@8M+:FJG6?"1 M!#%P?2MD? ,CFD88R4M*(S9B$#I$4SD&;?)4)32 TT2+G*><"SP:>#[S&3.7 M) QS'R=^:YLD:4D1P2.&01S$PFCCC-D=.067^DKAE;!="D@ M1OK( ;4[O[T;N>%"@LI@1V7G D$1D8#4#+-][9;(7&?:T/MK9HBQHQSB_8R0 M(SHL&S)2(/J%L?:,_D\-$C.I;)";R?>+(KU9&ED/-[\6O-6]D+]OWQUM#%Q( M3?C.772LFF1UL"<"*W6$8M[<@N>:*;=:<^O5RD*%*T_+.+':AG).%+PSG#A0 MT_;95X?@9F"3Z52CRRJ6%\U3C.[E>!!I5
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end